Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Orthofix Medical (OFIX) Shares Outstanding (Weighted Average) (2016 - 2026)

Orthofix Medical has reported Shares Outstanding (Weighted Average) over the past 18 years, most recently at $40.4 million for Q1 2026.

  • For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.22% year-over-year to $40.4 million, compared with a TTM value of $40.4 million through Mar 2026, up 3.22%, and an annual FY2025 reading of $39.6 million, up 3.85% over the prior year.
  • Shares Outstanding (Weighted Average) came in at $40.4 million for Q1 2026, up from $39.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $40.4 million in Q1 2026 to a low of $19898.0 in Q1 2022.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $37.7 million (2024), compared with a mean of $26.2 million.
  • The sharpest move saw Shares Outstanding (Weighted Average) plummeted 99.9% in 2022, then soared 186079.84% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $20.1 million in 2022, then surged by 83.16% to $36.7 million in 2023, then grew by 3.82% to $38.1 million in 2024, then rose by 3.85% to $39.6 million in 2025, then increased by 2.14% to $40.4 million in 2026.
  • Per Business Quant, the three most recent readings for OFIX's Shares Outstanding (Weighted Average) are $40.4 million (Q1 2026), $39.6 million (Q4 2025), and $39.8 million (Q3 2025).